Regeneron Pharmaceuticals (REGN) Total Liabilities (2009 - 2026)

Regeneron Pharmaceuticals' Total Liabilities history runs 18 years deep, the most recent figure standing at $9.4 billion for Q1 2026.

• In Q1 2026, Total Liabilities rose 15.78% year-over-year to $9.4 billion; the TTM figure through Mar 2026 stood at $9.4 billion (up 15.78% YoY), while the FY2025 annual figure was $9.3 billion, up 10.66% from the prior year.
• Total Liabilities was $9.4 billion for Q1 2026 at Regeneron Pharmaceuticals, up from $9.3 billion in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $9.4 billion in Q1 2026 to a low of $6.2 billion in Q3 2022.
• Historically, Total Liabilities has averaged $7.6 billion across 5 years, with a median of $7.4 billion in 2024.
• The sharpest annual moves came in 2022 and 2024: Total Liabilities slipped 2.72% in 2022, then increased 18.7% in 2024.
• A 5-year view of Total Liabilities shows it stood at $6.6 billion in 2022, then gained by 8.5% to $7.1 billion in 2023, then grew by 18.27% to $8.4 billion in 2024, then advanced by 10.66% to $9.3 billion in 2025, then gained by 1.54% to $9.4 billion in 2026.
• The last three Total Liabilities figures came in at $9.4 billion (Q1 2026), $9.3 billion (Q4 2025), and $9.2 billion (Q3 2025), per Business Quant data.